FORBES-TATE

Lobbying for HALOZYME THERAPEUTICS, INC. · U.S. Biotechnology Company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $80,000.00 income · posted Jul 20, 2026

Lobbying activity 2

Medicare/Medicaid

Issues related to coverage and reimbursement.

Health Issues

Issues related to biopharmaceutical research, development, and manufacturing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.